Chemexpress(SH:688131) Zheng Quan Zhi Xing·2025-08-01 16:23Core Viewpoint - The announcement details the results of the second vesting period of the 2023 restricted stock incentive plan for Shanghai Haoyuan Pharmaceutical Co., Ltd, including the number of shares to be listed and the relevant procedures for vesting and stock issuance [1][2][3]. Group 1: Stock Listing and Vesting Details - The total number of shares to be listed for trading is 527,660 shares, with the listing date set for August 6, 2025 [1][12]. - The second vesting period for the restricted stock was completed on July 31, 2025, and the company has received the necessary registration proof from the Shanghai branch of China Securities Depository and Clearing Corporation [1][11]. - The total number of shares vested in this period is 52.7660 million shares, which represents 50% of the total granted shares [8]. Group 2: Decision-Making Process - The decision-making process for the vesting involved multiple meetings, including the board of directors and the supervisory board, which approved the relevant proposals regarding the incentive plan [2][4]. - The independent directors provided their consent to the proposals related to the 2023 incentive plan [2][4]. - The company conducted an internal public notice regarding the list of proposed incentive recipients, with no objections received during the notice period [3]. Group 3: Financial Impact and Share Capital Changes - Following the vesting, the total share capital of the company increased from 211,571,033 shares to 212,098,693 shares [9][11]. - The company reported a net profit attributable to shareholders of 62,384,400.02 yuan for the first quarter of 2025, with basic earnings per share of 0.30 yuan per share [11]. - The new shares will dilute the earnings per share based on the increased total share capital while keeping the net profit unchanged [11].